Cellectar, a Madison biotech company developing a shot-in-the-arm treatment for cancer, is about to take a big leap forward, thanks to a healthy wad of cash, a one-of-a-kind machine and a new, well-credentialed chief executive with big hopes and plans. Cellectar is a UW-Madison spinoff company.
Office of Strategic Communication